JP2013163673A5 - - Google Patents

Download PDF

Info

Publication number
JP2013163673A5
JP2013163673A5 JP2013024857A JP2013024857A JP2013163673A5 JP 2013163673 A5 JP2013163673 A5 JP 2013163673A5 JP 2013024857 A JP2013024857 A JP 2013024857A JP 2013024857 A JP2013024857 A JP 2013024857A JP 2013163673 A5 JP2013163673 A5 JP 2013163673A5
Authority
JP
Japan
Prior art keywords
peptide
amino acid
seq
acid sequence
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013024857A
Other languages
English (en)
Japanese (ja)
Other versions
JP5738333B2 (ja
JP2013163673A (ja
Filing date
Publication date
Priority claimed from GB0516527A external-priority patent/GB0516527D0/en
Priority claimed from GB0609921A external-priority patent/GB0609921D0/en
Priority claimed from GB0609920A external-priority patent/GB0609920D0/en
Application filed filed Critical
Publication of JP2013163673A publication Critical patent/JP2013163673A/ja
Publication of JP2013163673A5 publication Critical patent/JP2013163673A5/ja
Application granted granted Critical
Publication of JP5738333B2 publication Critical patent/JP5738333B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013024857A 2005-08-11 2013-02-12 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド Expired - Fee Related JP5738333B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0516527A GB0516527D0 (en) 2005-08-11 2005-08-11 Peptides
GB0516527.9 2005-08-11
GB0609920.4 2006-05-18
GB0609921A GB0609921D0 (en) 2006-05-18 2006-05-18 Peptides
GB0609921.2 2006-05-18
GB0609920A GB0609920D0 (en) 2006-05-18 2006-05-18 Peptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008525635A Division JP2009505640A (ja) 2005-08-11 2006-08-09 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド

Publications (3)

Publication Number Publication Date
JP2013163673A JP2013163673A (ja) 2013-08-22
JP2013163673A5 true JP2013163673A5 (https=) 2014-03-06
JP5738333B2 JP5738333B2 (ja) 2015-06-24

Family

ID=37056087

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008525635A Pending JP2009505640A (ja) 2005-08-11 2006-08-09 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド
JP2013024857A Expired - Fee Related JP5738333B2 (ja) 2005-08-11 2013-02-12 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008525635A Pending JP2009505640A (ja) 2005-08-11 2006-08-09 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド

Country Status (17)

Country Link
US (1) US9243062B2 (https=)
EP (3) EP2594591B1 (https=)
JP (2) JP2009505640A (https=)
KR (2) KR20080039978A (https=)
CN (1) CN105017423B (https=)
AU (1) AU2006277785B2 (https=)
BR (1) BRPI0614366A2 (https=)
CA (1) CA2618796C (https=)
CU (1) CU23793B7 (https=)
CY (1) CY1120640T1 (https=)
DK (1) DK2594591T3 (https=)
EA (1) EA015629B1 (https=)
ES (1) ES2679994T3 (https=)
GB (1) GB2429013C (https=)
IL (3) IL189407A (https=)
NZ (3) NZ595387A (https=)
WO (1) WO2007017686A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2154969B1 (en) 2007-05-16 2015-11-18 The Brigham and Women's Hospital, Inc. Treatment of synucleinopathies
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2527366B1 (en) * 2007-06-12 2017-08-16 AC Immune S.A. Monoclonal anti beta amyloid antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
US20110256577A1 (en) * 2008-11-05 2011-10-20 Fujirebio Inc. Method for sensing a biochemical and/or biomechanical process of a biological material and method for analyzing biological materials
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2012047732A2 (en) * 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
JP5937106B2 (ja) * 2011-01-20 2016-06-22 サイレックス ラボラトリーズ，エルエルシー グルテン感受性の検出およびグルテン感受性とセリアック病を鑑別するための方法ならびに装置
KR102437522B1 (ko) * 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
JP6153019B2 (ja) 2013-01-31 2017-06-28 国立大学法人 東京大学 リゾホスファチジルセリン受容体機能調節活性を有する化合物
ES2729797T3 (es) * 2013-12-20 2019-11-06 Dev Ct Biotechnology Anticuerpos específicos de la alfa-enolasa y métodos de uso en terapias contra el cáncer
WO2015114576A1 (en) * 2014-01-31 2015-08-06 Universität Zürich Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease
JP6369721B2 (ja) 2014-07-04 2018-08-08 国立大学法人 東京大学 リゾホスファチジルセリン誘導体
GB2532426B (en) * 2014-11-18 2016-11-02 Rogers Arpi Therapeutic homodimer and uses thereof
WO2016108894A1 (en) * 2014-12-31 2016-07-07 Develpment Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
US9527922B2 (en) 2014-12-31 2016-12-27 Development Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
JP6404950B2 (ja) * 2015-01-21 2018-10-17 ギル メディカル センターＧｉｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ ホスファチジルイノシトールリン酸結合物質の細胞死滅検出用途
JP6544669B1 (ja) 2018-03-16 2019-07-17 ディヴェロップメント センター フォー バイオテクノロジー アルファエノラーゼに特異的な抗体及びその使用
WO2019197610A1 (en) 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) New vaccinal strategy
CN110885778A (zh) * 2018-09-07 2020-03-17 上海益诺思生物技术股份有限公司 从体外培养的细胞中分离Pig-a基因突变细胞的方法
JP7796008B2 (ja) * 2019-09-13 2026-01-08 メモリアル スローン ケタリング キャンサー センター 抗ｃｄ３７１抗体およびその使用
GB202015755D0 (en) * 2020-10-05 2020-11-18 Rogers Arpi Coronavirus therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0463056A1 (en) 1989-03-17 1992-01-02 E.I. Du Pont De Nemours And Company External regulation of gene expression
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
SE9102074D0 (sv) * 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5891623A (en) 1992-11-09 1999-04-06 Consorzio Per Le Biotecnologie Diagnosis and treatment of AIDS onset
GB9317423D0 (en) 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US6001809A (en) 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
USRE39048E1 (en) * 1995-06-07 2006-03-28 Pepscan Systems B.V. Peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine
US5861260A (en) * 1996-11-05 1999-01-19 University Of Massachusetts Diagnostic methods for screening patients for scleroderma
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
NZ501424A (en) * 1997-07-21 2005-08-26 Arpi Matossian Rogers Ligands, including antibodies, showing reactivity against anti-TCR V-beta antibody
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
IL148079A0 (en) * 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
PT1232392E (pt) 1999-10-12 2003-08-29 Connex Ges Optimierung Von For Processo melhorado para deteccao nas fezes de bacterias do genero helicobacter resistentes ao acido
EP1130032A1 (en) 2000-02-28 2001-09-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR)
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
JP2001299349A (ja) * 2000-04-19 2001-10-30 Suntory Ltd 新規組換え型抗体とそのｃｄｒのアミノ酸配列およびそれをコードする遺伝子
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040115196A1 (en) * 2001-04-18 2004-06-17 Yoshiaki Fukuda Novel recombinant antibodies, amino acid sequences of cdrs thereof and genes encoding the same
EP2277542B1 (en) * 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
IL159422A0 (en) 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
BR0312985A (pt) * 2002-07-26 2005-06-21 Inst Medical W & E Hall Métodos para extrair ou induzir, em um mamìfero, uma resposta imune dirigida a um parasita, para tratar de modo terapêutico ou profilático um mamìfero para infecção por parasitas, para o tratamento e/ou a profilaxia de uma condição doentia de mamìfero, uso de uma composição,composição, composição de vacina, composição farmacêutica, anticorpo para inibir, parar ou retardar o inìcio ou progressão de uma condição doentia de mamìfero, uso de um anticorpo, métodos para detectar, em uma amostra bológica, uma molécula imunointerativa dirigida a um microorganismo e para detectar, monitorar ou de outra forma avaliar uma resposta imune dirigida a um microorganismo em um indivìduo, kit modular, método para analisar, projetar e/ou modificar um agente capaz de interagir com um sìtio de ligação de molécula imunointerativa anti-gpi glicano, e, uso do agente
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
WO2005035732A2 (en) * 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
KR100500283B1 (ko) 2003-03-25 2005-07-11 이뮤노믹스 주식회사 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물
KR100872210B1 (ko) 2003-04-23 2008-12-05 메다렉스, 인코포레이티드 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체
CA2528182A1 (en) 2003-06-06 2005-06-16 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen sm5-1 and uses thereof
AU2004261229A1 (en) * 2003-07-29 2005-02-10 Eisai, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
US9403908B2 (en) 2003-09-29 2016-08-02 The Regents Of The University Of California Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration
KR101413844B1 (ko) * 2008-12-09 2014-06-30 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신

Similar Documents

Publication Publication Date Title
JP2013163673A5 (https=)
JP2017527272A5 (https=)
JP2008538919A5 (https=)
RU2016149596A (ru) Новые полипептиды со специфическим связыванием и пути их применения
EP4249064A2 (en) Novel fusion protein specific for cd137 and pd-l1
JP2021514618A5 (https=)
JP2017518748A5 (https=)
HRP20120020T1 (hr) Visokoosjetljivi imunoeseji i kompleti za određivanje peptida i proteina od biološkog interesa
JP2010530220A5 (https=)
CN107847590A (zh) 针对白细胞介素36受体（il‑36r）的抗体
JP2006516195A5 (https=)
JP2004519475A5 (https=)
JP2013535963A5 (https=)
CA2506580A1 (en) Assay kit and antibody for human low molecular weight cd14
PT1881064E (pt) Anticorpo monoclonal anti-núcleo de hcv
JPWO2019169314A5 (https=)
Milovnik et al. Selection and characterization of DARPins specific for the neurotensin receptor 1
JP2013511966A5 (https=)
US8183055B2 (en) Peptide aptamer for neutralizing the binding of platelet antigen specific antibodies and diagnostic and therapeutic applications containing the same
CN110049995A (zh) 哺乳动物表达的新型人类免疫缺陷病毒包膜蛋白抗原
ES2561497T3 (es) Ligandos monovalentes del receptor CD28 humano
JP2008515388A5 (https=)
JP2017536821A5 (https=)
EP1560025A3 (en) Specific markers for diabetes
JP2020500150A (ja) 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド